MarketDifamilast
Company Profile

Difamilast

Difamilast, sold under the brand name Moizerto among others, is a medication used for the treatment of atopic dermatitis. Difamilast is a non-steroidal topical phosphodiesterase 4 (PDE4) inhibitor. Difamilast was discovered and developed by Otsuka Pharmaceutical.

Medical uses
Difamilast is indicated for the topical treatment of people with mild to moderate atopic dermatitis. == Society and culture ==
Society and culture
Legal status Difamilast was approved for medical use in Japan in September 2021, Difamilast is sold under the brand names Moizerto (JP) and Adquey (US). == References ==
tickerdossier.comtickerdossier.substack.com